Genelife Clinical Research Pvt. Ltd.

This week is World Breastfeeding Week — and it is a good moment to acknowledge something the clinical research community does not discuss often enough.

The science behind breastfeeding is still evolving. Human milk science, maternal nutrition, neonatal microbiome development, the immunological properties of colostrum — these are active areas of clinical research with significant evidence gaps that directly affect how millions of mothers and newborns are supported around the world.

At Genelife, we work across maternal health, neonatal care, nutraceutical clinical evidence, and women's health research. The intersection of good science and early-life health outcomes is one of the most important frontiers in clinical research — and one where the evidence base still has a long way to go.

On World Lung Cancer Day, one statistic stands out above all others:

LungCancer kills more people globally each year than colon, breast, and prostate cancer combined.

And yet it remains one of the most underfunded and stigmatised cancers — partly because of the persistent assumption that it only affects smokers. It doesn't. Non-smokers account for a significant share of diagnoses, linked to radon exposure, air pollution, secondhand smoke, and genetic factors that have nothing to do with cigarettes.

The single most impactful weapon we have is early detection. When caught early, survival rates improve dramatically. When caught late — as most cases still are — options narrow significantly.

At Genelife Clinical Research, we are proud to support oncology clinical research that brings better diagnostics and treatments to patients who need them. Every clinical trial we support is a step toward better outcomes for real people living with this disease.

Is your clinical trial data telling the whole story?

Randomised controlled trials prove efficacy under controlled conditions. But what happens when your drug meets real patients — with comorbidities, polypharmacy, and diverse lifestyles?

That's where Real World Evidence comes in.

At Genelife Clinical Research, we help global pharma and biotech companies bridge the gap between clinical trial results and real-world outcomes — through patient registries, observational studies, disease burden mapping, and market research that captures how treatments actually perform in practice.

BA/BE studies are not the simple, low-risk end of pharmaceutical clinical research.

They are scientifically precise, operationally demanding, and highly sensitive to design and execution errors. And because the regulatory acceptance criterion — a 90% confidence interval for AUC and Cmax within 80–125% — is fixed and statistical, there is no room to compensate for a poorly designed study with a well-written report.

The most common and costly failures:

→ Variability assumptions that were too optimistic — resulting in an underpowered study that cannot achieve the required confidence interval → Site selection decisions made on cost rather than capability — generating data quality issues that regulators query → Bioanalytical method validation gaps that undermine the credibility of the entire PK dataset → Protocol deviations during execution that require explanation and, in some cases, invalidate individual subject data

The one that gets underestimated most consistently:

Operator dependency.

In a pharmaceutical trial, you randomize patients. The drug is the same regardless of who prescribes it.

In a device trial, you also have to manage — implicitly — the randomization of operator skill. And you can't. A stent deployed by an experienced interventional cardiologist at a high-volume center produces different outcomes than the same stent deployed by a less experienced operator. A surgical robot's performance depends on technique, intraoperative decisions, and learning curve effects that vary systematically across operators.

The consequence: trial outcomes that reflect operator skill as much as device performance. Evidence that is not reproducible in the broader clinical community. Pivotal trial results that look different from post-market registry data — not because the device changed, but because the operator base did.

Managing this requires explicit design choices. Pre-defined operator qualification criteria. Structured proctoring. Centre-level outcome monitoring. Pre-specified analysis of outcomes by operator volume.

The trials that get this right produce evidence that is both more scientifically honest and more regulatory-credible.

#MedicalDevices #ClinicalTrials #DeviceResearch #ClinicalResearch #EUMDR #FDA #CDSCO #CRO

India isn't one epidemiological environment. It's at least three.

A still-substantial infectious disease burden — dengue, TB, vector-borne disease — that requires classical surveillance methodology. A rapidly accelerating non-communicable disease epidemic — diabetes, cardiovascular disease, CKD — that looks meaningfully different than it did five years ago. And a population scale and genetic diversity that makes safety signal detection and subgroup analysis possible in ways smaller markets simply can't support.

India's medicinal plant tradition documented cardiovascular disease management in 500 BCE.

It identified cognitive enhancers — Brahmi, Ashwagandha — centuries before the term nootropic existed.

It described hepatoprotective herbs whose mechanisms modern pharmacology is still characterizing.

There's a paradox at the center of the global botanical nutraceutical market.

The ingredients generating the most commercial interest internationally — ashwagandha, curcumin, boswellia, brahmi, moringa — have their deepest roots in India. The traditional knowledge, the raw material supply chains, the phytochemical expertise, and the processing infrastructure are concentrated in India to a degree no other country approaches.

Yet most of the clinical evidence for these ingredients has been generated in Western research settings — often with Indian-sourced material, studied in Western populations, under Western regulatory frameworks.

That's changing. And this article makes the case for why India is actually the right place to generate clinical evidence for these ingredients — not just the cheapest place.

The ingredient expertise is here. The raw material supply chains are here. The patient populations most relevant to adaptogen, metabolic, and inflammatory research are here. And an internationally credible clinical research infrastructure that generates data acceptable to FDA, EMA, and TGA is here too.

For international nutraceutical companies building clinical programs around botanical ingredients, India isn't just a cost play. It's the location where everything aligns.

India isn't one epidemiological environment for research sponsors. It's at least three.

A still-significant infectious disease burden that demands classical outbreak surveillance. A non-communicable disease epidemic accelerating faster than almost anywhere in the world. And a population scale and genetic diversity that makes safety signal detection possible in ways smaller markets simply cannot support.

For international sponsors working on post-marketing safety surveillance, disease burden studies, or real-world evidence generation, understanding this landscape — and designing research that meets international reporting and regulatory standards — is the difference between data that's interesting and data that's usable.